Physician profile
Nealya L Bell-Silva
NPI 1679738264
$107,264.04
in general payments reported to CMS, 2019-2025
6 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,544 · 2023: $32K · 2024: $28K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Travel and Lodging: $17K · Food and Beverage: $2,289 · Long Term Medical Supply Or Device Loan: $84.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,190.78 |
| Travel and Lodging | $17,155.73 |
| Food and Beverage | $2,289.23 |
| Long Term Medical Supply Or Device Loan | $84.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gen-Probe, INC. | $87,975.73 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Hologic Sales and Service, LLC | $19,098.36 | 2022-2025 | Aptima, Btx, Fetal Fibronectin Enzyme Immunoassay |
| Baxter Healthcare | $84.47 | 2025 | Hillrom - Oae Hearing Screener |
| Novo Nordisk INC | $53.93 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $37.11 | 2025 | Mounjaro |
| Radius Health, INC. | $14.44 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nealya Bell-Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.